{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T18:28:06Z","timestamp":1771698486983,"version":"3.50.1"},"reference-count":33,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1736,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,1]]},"DOI":"10.1111\/j.1365-2036.2010.04516.x","type":"journal-article","created":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T10:42:19Z","timestamp":1291113739000},"page":"203-212","source":"Crossref","is-referenced-by-count":27,"title":["Randomised clinical trial: a novel rabeprazole extended release 50\u2003mg formulation vs. esomeprazole 40\u2003mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies"],"prefix":"10.1111","volume":"33","author":[{"given":"L.","family":"Laine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. O.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ibegbu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Chou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Rossiter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,30]]},"reference":[{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1365-2036.2000.00856.x","article-title":"Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators","volume":"14","author":"Kahrilas","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","article-title":"Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial","volume":"96","author":"Richter","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","article-title":"Esomeprazole (40\u2003mg) compared with lansoprazole (30\u2003mg) in the treatment of erosive esophagitis","volume":"97","author":"Castell","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2005.02368.x","article-title":"A randomized comparative study of esomeprazole 40\u2003mg versus pantoprazole 40\u2003mg for healing erosive oesophagitis: the EXPO study","volume":"21","author":"Labenz","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB5|cit5","unstructured":"Nexium (esomeprazole magnesium) delayed release capsules approval package, NDA Application No.: 21-153 & 21-154 http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2001\/21154_Nexium.cfm"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2036.2005.02339.x","article-title":"Efficacy of esomeprazole 40\u2003mg vs. lansoprazole 30\u2003mg for healing moderate to severe erosive oesophagitis","volume":"21","author":"Fennerty","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/j.1365-2036.2006.03235.x","article-title":"Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive esophagitis","volume":"25","author":"Katz","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2036.2009.03933.x","article-title":"Clinical trials: healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation - results from two randomized controlled studies","volume":"29","author":"Sharma","year":"2008","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1136\/gut.38.5.649","article-title":"Relation between oesophageal acid exposure and healing of oesophagitis with omeprazole in patients with severe reflux oesophagitis","volume":"38","author":"Holloway","year":"1996","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1001\/archinte.159.7.649","article-title":"Importance of pH control in the management of GERD","volume":"159","author":"Hunt","year":"1999","journal-title":"Arch Intern Med"},{"issue":"Suppl. 5","key":"10.1111\/j.1365-2036.2010.04516.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1365-2036.2004.02140.x","article-title":"Review article: gastric pH- the most relevant predictor of benefit in reflux disease","volume":"20","author":"Armstrong","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2036.2010.04367.x","article-title":"A model of healing of Los Angeles grades C and D reflux oesophagitis: is there an optimal time of acid suppression for maximal healing?","volume":"32","author":"Katz","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2036.2010.04516.x-BIB13|cit13","first-page":"S-648","article-title":"Comparison of 24-hour intragastric pH following once-daily treatment with esomeprazole, rabeprazole delayed release, and six rabeprazole extended-release formulations","volume":"138","author":"Morelli","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1053\/gast.1996.v111.pm8698230","article-title":"The endoscopic assessment of esophagitis: a progress report on observer agreement","volume":"111","author":"Armstrong","year":"1996","journal-title":"Gastroenterology"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/gut.45.2.172","article-title":"Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification","volume":"45","author":"Lundell","year":"1999","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0016-5107(02)70110-7","article-title":"Comparison of inter- and intraobserver consistency for grading of esophagitis by expert and trainee endoscopists","volume":"56","author":"Pandolfino","year":"2002","journal-title":"Gastrointest Endosc"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/S0016-5107(04)01289-1","article-title":"Comparison of interobserver agreement for different scoring systems for reflux esophagitis: impact of level of experience","volume":"60","author":"Rath","year":"2004","journal-title":"Gastrointest Endosc"},{"issue":"Suppl. 4","key":"10.1111\/j.1365-2036.2010.04516.x-BIB18|cit18","first-page":"iv28","article-title":"Assessment of reflux symptom severity: methodological options and their attributes","volume":"53","author":"Bytzer","year":"2004","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1046\/j.1365-2036.2004.01861.x","article-title":"Systematic review: do we need a new gastro-oesophageal reflux disease questionnaire?","volume":"19","author":"Stanghellini","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB20|cit20","unstructured":"Food and Drug Administration (FDA) Guidance for Industry: non-inferiority clinical trials draft guidance http:\/\/www.fda.gov\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/default.htm"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB21|cit21","unstructured":"Committee for Proprietary Medicinal Products (CPMP) Points to consider on switching between superiority and non-Inferiority http:\/\/www.emea.europa.eu\/pdfs\/human\/ewp\/048299en.pdf"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.1315","article-title":"Some fundamental issues with non-inferiority testing in active controlled trials","volume":"22","author":"Hung","year":"2003","journal-title":"Stat Med"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1037\/1082-989X.3.4.486","article-title":"Fixed and random effects models in meta analysis","volume":"3","author":"Hedges","year":"1998","journal-title":"Psychol Methods"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB24|cit24","volume-title":"Prescribing Information for Prevacid\u00ae (Lansoprazole)","author":"TAP Pharmaceutical Product Inc","year":"2006"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB25|cit25","volume-title":"Prescribing Information for Prilosec\u00ae (Omeprazole)","author":"AstraZeneca","year":"2001"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB26|cit26","volume-title":"Prescribing Information for Prontonix\u00ae (Pantoprazole Sodium)","author":"Wyeth Laboratories","year":"2004"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB27|cit27","volume-title":"Prescribing Information for Aciphex\u00ae (Rabeprazole)","author":"Eisai Inc","year":"2007"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/j.1572-0241.2006.00528.x","article-title":"Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and meta-analysis","volume":"101","author":"Gisbert","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1136\/gut.2005.078626","article-title":"Accuracy of breath tests using low doses of 13C-urea to diagnose Helicobacter pylori infection: a randomised controlled trial","volume":"55","author":"Gatta","year":"2006","journal-title":"Gut"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.1440-1746.2005.03547.x","article-title":"13C-urea breath test: reproducibility and association with the severity of Helicobacter pylori-associated antral gastritis","volume":"20","author":"Matthews","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"issue":"Suppl. s1","key":"10.1111\/j.1365-2036.2010.04516.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2036.2005.02607.x","article-title":"Review article: Helicobacter pylori and gastro-oesophageal reflux disease","volume":"22","author":"Delaney","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1093\/oxfordjournals.bmb.a011663","article-title":"Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy","volume":"54","author":"McColl","year":"1998","journal-title":"Br Med Bull"},{"key":"10.1111\/j.1365-2036.2010.04516.x-BIB33|cit33","volume-title":"Prescribing Information for Dexlant\u00ae (Dexlansoprazole)","author":"Takeda Pharmaceuticals America","year":"2010"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2010.04516.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2036.2010.04516.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T21:56:35Z","timestamp":1625435795000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2010.04516.x"}},"subtitle":["Randomised clinical trial: rabeprazole-ER for moderate-severe oesophagitis"],"short-title":[],"issued":{"date-parts":[[2010,11,30]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04516.x","relation":{},"ISSN":["0269-2813"],"issn-type":[{"value":"0269-2813","type":"print"}],"subject":[],"published":{"date-parts":[[2010,11,30]]}}}